Scarica l'app Stockscreener
3.89
6.49%
-0.27
Precedente Chiudi:
$4.16
Aprire:
$4.13
Volume 24 ore:
237.55K
Relative Volume:
0.64
Capitalizzazione di mercato:
$238.91M
Reddito:
$45.15M
Utile/perdita netta:
$-39.23M
Rapporto P/E:
-2.1268
EPS:
-1.829
Flusso di cassa netto:
$-18.93M
1 W Prestazione:
+9.58%
1M Prestazione:
+45.15%
6M Prestazione:
-46.71%
1 anno Prestazione:
-25.05%
Intervallo 1D:
$3.87
$4.38
Intervallo di 1 settimana:
$3.47
$4.455
Portata 52W:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Nome
Trisalus Life Sciences Inc
Settore
Industria
Telefono
415 336 8917
Indirizzo
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
3.89 | 257.95M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Lake Street | Buy |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-11 | Iniziato | ROTH MKM | Buy |
| 2024-10-25 | Iniziato | Northland Capital | Outperform |
| 2024-09-16 | Iniziato | Oppenheimer | Outperform |
| 2024-05-30 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Trisalus Life Sciences Inc Borsa (TLSI) Ultime notizie
TriSalus Life Sciences Warrants (TLSIW) Hold Steady Near Support in Quiet TradingAndrews Pitchfork - newsline.com
TLSI Q1 2026 Earnings: EPS Surprise of 118.86% Drives Stock HigherAnalyst Drop Coverage - newsline.com
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by 118.86% - newsline.com
TriSalus Life Sciences (TLSI) Gains 2.88% as Stock Approaches Key Resistance LevelWave Extension - newsline.com
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer - Stock Titan
TriSalus Life Sciences Inc. (TLSI) Q1 2026 Earnings: Strong EPS Surprise Driven by Operational ProgressFree Cash Flow Trends - newsline.com
TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc. - GlobeNewswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation | NDAQ:TLSI | Press Release - Stockhouse
TLSI News | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TSLI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-06-01 | Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation | NDAQ:TLSI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
TLSI Q1 2026 Earnings: Surprise Profit Beats Analyst Estimates, Shares RallySurprise Factor Analysis - newsline.com
Number of shareholders of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences Q1 2026 Earnings: Surprise EPS Profit of $0.03 Beats Estimates by 118.9%Forward Guidance Trends - newsline.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Stockholders to Connect - ACCESS Newswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences (TLSI) Falls Over 5% as Stock Tests Key Support Near $3.10Stop Hunt - The Legal Advocate
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance - Pluang
TLSI Q1 2026 Earnings: EPS Surprises Positively Despite No Revenue, Stock DeclinesProfit Warning Alert - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (RLSI) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life - The National Law Review
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: EPS Surges Past Expectations, Yet Stock SlipsEBITDA Margin Trends - Newser
TLSI (TLSI) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Certain Stock Options of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
Certain Stock Warrants of TriSalus Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 22-MAY-2026. - marketscreener.com
James Pallotta reports 5.2% stake in TriSalus Life Sciences (TLSI) - Stock Titan
38 startups join Innosphere life-sciences incubator - BizWest
Levi & Korsinsky Announces Investigation of Securities Claims Against TLSI (TLSI) - GlobeNewswire
TriSalus (TLSI) CCO reports 543-share tax-withholding sale, retains over 125K shares - Stock Titan
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud - Business Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock Price Today & Analysis - Gotrade
TLSI Insider Buying Surge: 5 Executives Purchase $1.3M in Stock - Meyka
TriSalus Life Sciences Director Purchased Shares Worth Over $1.5M - TradingView
TriSalus Life Sciences (TLSI) director buys 10,000 shares in open market - Stock Titan
Director Mats Wahlstrom boosts TriSalus (TLSI) stake with 60,000-share open-market buy - Stock Titan
TriSalus (TLSI) director and LLC add 610K shares in open-market buys - Stock Titan
TriSalus (TLSI) CEO Mary Szela adds 39,682 shares in open-market stock purchase - Stock Titan
TriSalus (TLSI) CFO adds 7,100 shares in open-market purchase - Stock Titan
Earnings call transcript: TriSalus Life Sciences Q1 2026 sees stock gain despite revenue dip By Investing.com - Investing.com Australia
Trisalus Life Sciences Inc Azioni (TLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Trisalus Life Sciences Inc Azioni (TLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):